Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Organon & Co. OGN
$20.77
-$0.1 (-0.48%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
5434095910.00000000
-
week52high
39.09
-
week52low
20.96
-
Revenue
6174000000
-
P/E TTM
6
-
Beta
0.00000000
-
EPS
3.59000000
-
Last Dividend
1.12000000
-
Next Earnings Date
04 мая 2023 г. в 12:30
Описание компании
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| B of A Securities | Neutral | Buy | 05 авг 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 08 июл 2022 г. |
| Goldman Sachs | Buy | 27 апр 2022 г. | |
| Morgan Stanley | Equal-Weight | Equal-Weight | 06 апр 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 22 февр 2022 г. |
| Piper Sandler | Overweight | Neutral | 06 сент 2022 г. |
| B of A Securities | Underperform | Neutral | 14 окт 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 12 окт 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 04 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| WALSH MATTHEW M | D | 22343 | 22343 | 05 авг 2022 г. |
| WALSH MATTHEW M | D | 31706 | 10790 | 05 авг 2022 г. |
| WALSH MATTHEW M | A | 42496 | 22343 | 05 авг 2022 г. |
| Stahler Rachel A | D | 12890 | 12890 | 05 авг 2022 г. |
| Stahler Rachel A | D | 18950 | 4416 | 05 авг 2022 г. |
| Stahler Rachel A | A | 23366 | 12890 | 05 авг 2022 г. |
| Sharp Shalini | A | 14935 | 5640 | 10 июн 2022 г. |
| Whiteford Grace Puma | A | 14638 | 5640 | 10 июн 2022 г. |
| Patton Cynthia M | A | 14638 | 5640 | 10 июн 2022 г. |
| McGarry Martha E | A | 14638 | 5640 | 10 июн 2022 г. |
Новостная лента
Organon: Too Cheap To Ignore
Seeking Alpha
07 февр 2023 г. в 08:05
Organon has a solid portfolio driven by steady established brands and fast-growing Women's Health. Management is exercising balance sheet discipline by paying down debt all while maintaining a very well covered dividend.
Is There Anything Organic Or Interesting About Organon?
Seeking Alpha
07 февр 2023 г. в 04:01
Organon is a business I own - but only due to being awarded a significant number of shares, some of which I actually sold early on. I kept a stake. In this article, I'm going to follow a subscriber request and dive into what Organon might do for its shareholders, if you did not sell, or may be interested.
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 16, 2023
Business Wire
06 февр 2023 г. в 07:30
JERSEY CITY, N.J.--( BUSINESS WIRE )--Organon (NYSE: OGN), a global women's healthcare company will release its fourth quarter and full year 2022 financial results on February 16, 2023, prior to the company's webcast and conference call scheduled for 8:30 a.m. EST.
Will Organon (OGN) Beat Estimates Again in Its Next Earnings Report?
Zacks Investment Research
27 янв 2023 г. в 13:33
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Organon & Co. (OGN) CEO Kevin Ali Presents at 41st Annual J.P. Morgan Healthcare Conference (Transcript)
Seeking Alpha
10 янв 2023 г. в 15:10
Organon & Co. (NYSE:OGN ) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 10:30 AM ET Company Participants Kevin Ali - CEO Matt Walsh - CFO Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody.